The U.S. government plans to spend up to $4.9 million preparing for clinical trials of ibogaine, a psychedelic drug being considered as a potential treatment for veterans with post-traumatic stress disorder. The funding will come from the Advanced Research Projects Agency for Health, but it will not pay for patient treatment or research involving human participants. PTSD can follow traumatic experiences and cause flashbacks, anxiety, nightmares and heightened stress responses. President Donald Trump set aside $50 million for ibogaine research in April, and the administration said in October it was moving toward the first federally funded trials of the drug for opioid addiction and PTSD.
Health Secretary Robert F. Kennedy Jr. said Mark Cuban Cost Plus Drug Company will develop methods to manufacture ibogaine in the United States. If the drug is approved, he said, its cost would be comparable to generic medicines. Separately, the National Institute of Mental Health has launched a $20 million program to study drugs including ketamine and psilocybin, with funding decisions expected in summer 2027. ARPA-H is also preparing another ibogaine research effort focused on substance-use disorders, which Kennedy said should be announced by the end of 2026. The funding announced so far supports groundwork for research, not evidence that ibogaine is safe or effective for PTSD.
Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.